Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Private Wealth

What are the main procedural steps in residency and domicile planning with Russian nexus in the pharmaceuticals sector?

Elizaveta Razina · March 2026 · 3 min read

Owners of Russian pharmaceutical businesses face distinct residency planning constraints. Key procedural steps for private clients. Make an enquiry.

For owners of privately held Russian companies in the pharmaceuticals sector, residency and domicile planning with a Russian nexus follows a defined procedural sequence. The planning is more constrained than in general private wealth structuring because the beneficial owner cannot sever operational ties with Russia in the same way as, say, a passive investor: the Russian pharmaceutical entity must remain licensed, staffed, and compliant throughout.

The six principal steps are: first, a tax residency assessment against Russian rules on physical presence; second, a pharmaceutical-specific licence and permit audit to map which Roszdravnadzor-issued authorisations attach to the legal entity versus the individual; third, a review of the existing ownership structure and any offshore or holding layer for consistency with Russian controlled foreign company legislation; fourth, an EAEU regulatory compliance mapping, given that pharmaceutical market authorisations within the Eurasian Economic Commission framework may impose independent constraints on corporate restructuring; fifth, the preparation and filing of any required notifications to Russian tax and regulatory authorities in connection with the residency change; and sixth, the design of an ongoing compliance monitoring arrangement for the period after the domicile shift takes effect.

Under Russian law, individual tax residency is determined by physical presence – typically 183 days within a calendar year on Russian territory. Losing Russian tax residency changes the individual's personal tax position but does not affect the regulatory obligations of the Russian pharmaceutical entity: licences issued by Roszdravnadzor attach to the legal entity, not the individual owner. Within the EAEU framework, pharmaceutical market authorisations follow supranational rules set by the Eurasian Economic Commission, which may independently constrain restructuring options even where Russian domestic law would otherwise permit the intended structure.

In practice, timing is the dominant concern. Pharmaceutical licence renewal cycles and EAEU registration periods create fixed deadlines that must be mapped against the planned residency change before any formal steps are initiated. Coordinating personal and corporate tracks from the outset – rather than addressing them sequentially – typically reduces both the planning timeline and the risk of a compliance gap in the pharmaceutical business during the transition.

For guidance specific to your situation, the firm's Private Wealth & Asset Protection practice advises on integrating the personal residency track with the pharmaceutical regulatory and corporate structuring tracks. Background analysis is available in our overview of residency and domicile planning with a Russian nexus and our practical guide to residency and domicile planning.

To discuss your specific circumstances in confidence – make an enquiry: info@vetrovpartners.com |

— Elizaveta Razina Senior Lawyer, Practice Lead — IP Enforcement, Vetrov & Partners vetrovpartners.com/razina/

Elizaveta Razina leads the firm's intellectual property practice, representing foreign trademark owners in infringement proceedings before Russian state courts and the IP Court. She advises on anti-counterfeiting strategy, asset protection structuring, and private wealth matters for clients with Russian nexus.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry